Atezolizumab, Obinutuzumab, and Venetoclax provide durable remissions for untreated DLBCL-RS pts

Atezolizumab + obinutuzumab + venetoclax in patients with R/R DLBCLПодробнее

Treating Richter’s transformation with venetoclax, obinutuzumab and atezolizumabПодробнее

Obinutuzumab plus venetoclax in early R/R DLBCLПодробнее

The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCLПодробнее

Epcoritamab monotherapy and combinations in R/R CLL and Richter’s syndromeПодробнее

Atezolizumab with R-GEMOX in patients with transformed DLBCLПодробнее

Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZLПодробнее

LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCLПодробнее

Atezolizumab with venetoclax and obinutuzumab in patients with CLLПодробнее

Does polatuzumab vedotin, venetoclax, and rituximab combined enhance tumor responses in R/R DLBCL?Подробнее

CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLLПодробнее

The use of NGS in the diagnosis and treatment of Richter’s transformationПодробнее

The final cut in cell divisionПодробнее

Acalabrutinib plus venetoclax and rituximab in MCL & the importance of chemotherapy-free regimensПодробнее

Are There CLL Clinical Trials Studying Richter’s Transformation?Подробнее

Atezolizumab plus bevacizumab in non-clear cell, sarcomatoid kidney cancerПодробнее

Evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in Richter's transformationПодробнее

Trial results of venetoclax plus CHOP therapy with rituximab or obinutuzumab in non-Hodgkin lymphomaПодробнее